RC(SZ:300596) Xin Lang Cai Jing·2025-10-21 00:35Performance Review - Company reported Q3 2025 revenue of 1.514 billion yuan, a year-on-year increase of 4.8% and flat quarter-on-quarter; net profit attributable to shareholders was 151 million yuan, corresponding to earnings per share of 0.66 yuan, a year-on-year increase of 60.8% and a quarter-on-quarter increase of 13.2%, in line with expectations [1] - For the first three quarters of 2025, revenue reached 4.509 billion yuan, a year-on-year increase of 5.7%; net profit attributable to shareholders was 392 million yuan, a year-on-year increase of 24.9%; and net profit excluding non-recurring items was 385 million yuan, a year-on-year increase of 27.7% [1] - Operating cash flow for the first three quarters of 2025 was 282 million yuan, a year-on-year decrease of 1.8% [1] Development Trends - Profit margin improvement trend is evident with increased capacity utilization and market expansion; the company's profit margin has shown an upward trend since 2025 due to the ramp-up of the Zhuhai base and the second phase of the Kangtai project [2] - The company has established a life sciences division in 2021 to cultivate a third growth curve, focusing on bioblocks and synthetic biology; it also made an indirect acquisition of Korean IPI Company to enter the high-end electronic-grade PI materials sector, with new production facilities expected to begin trial production in 2026 [2] - The company initiated an overseas expansion plan in February 2025, planning to invest up to 300 million USD in Malaysia to build an overseas R&D and production base, enhancing international competitiveness [2] Profit Forecast and Valuation - The company maintains its profit forecasts for 2025/26 unchanged, with the current stock price corresponding to price-to-earnings ratios of 16.8x and 14.3x for 2025/26; the target price has been raised by 25% to 47.5 yuan, indicating a potential upside of 17.5% and a 16.8x price-to-earnings ratio for 2026, maintaining an outperform rating [3]